APA (7th ed.) Citation

M, S., Y, T., P, S., H, C., S, L., X, L., . . . L, W. (2026). Shexiang Tongxin dropping pill for coronary microvascular disease: Rationale and design of a multicenter randomized trial with a cardiopulmonary exercise testing primary endpoint and AI-enhanced myocardial contrast echocardiograph. Frontiers in cardiovascular medicine, 13, 1875936. https://doi.org/10.3389/fcvm.2026.1875936

Chicago Style (17th ed.) Citation

M, Su, Tang Y, Sun P, Cen H, Liu S, Li X, Wang W, and Wang L. "Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-enhanced Myocardial Contrast Echocardiograph." Frontiers in Cardiovascular Medicine 13 (2026): 1875936. https://doi.org/10.3389/fcvm.2026.1875936.

MLA (9th ed.) Citation

M, Su, et al. "Shexiang Tongxin Dropping Pill for Coronary Microvascular Disease: Rationale and Design of a Multicenter Randomized Trial with a Cardiopulmonary Exercise Testing Primary Endpoint and AI-enhanced Myocardial Contrast Echocardiograph." Frontiers in Cardiovascular Medicine, vol. 13, 2026, p. 1875936, https://doi.org/10.3389/fcvm.2026.1875936.